Aciont® to Present at ARVO 2013 Annual Meeting

SALT LAKE CITY - April 16, 2013 - PRLog -- Aciont To Present at ARVO 2013 Annual Meeting
Salt Lake City, UT – April 15, 2013 – Aciont Inc. announced today that Dr. Sarah A. Molokhia and Dr. Kongnara Papangkorn will present recent findings on two Visulex-TM technologies pertaining to the iontophoretic delivery of macromolecules and the non invasive, passive diffusion-based method of delivering small molecules for the treatment of posterior uveitis, respectively, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle, WA on May 7th 2013.
Dr. Molokhia’s presentation entitled “The Influence of Formulation Factors on Transscleral Iontophoretic Delivery of a Macromolecule in Vitro and in Vivo” delves into using Iontophoresis as a minimally invasive means to deliver drugs through tissue using a mild electrical current. Molokhia currently works as a research scientist for Aciont Inc. This oral presentation will be on Tuesday, May 7th from 11:15 AM to 11:30 AM, during the Drug Delivery II session.

Dr. Papangkorn, Aciont’s Vice President of Product Development, will be presenting on “Noninvasive Dexamethasone Sodium Phosphate (DSP) Ocular Drug Delivery System for the Treatment of Intermediate and Posterior Uveitis.”  Dr. Papangkorn will give an overview of the severe intermediate and posterior uveitis signs and symptoms in the animal model used in the study.  Papangkorn’s presentation will show that uveitis can be subdued following two weekly doses of DSP-Visulex treatment while illustrating the potential benefit of this simple, non-invasive technology for posterior eye diseases in man.   Dr. Papangkorn’s presentation will also take place during the Drug Delivery II session, scheduled on Tuesday, May 7th from 11:45 AM to 12:00 PM. Both presentations will conclude with a “Q and A” session.


Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration.  Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance.  Aciont is located in Salt Lake City, Utah.  For more information, visit the company’s website at www.aciont.com.
Source:  Aciont Inc.

Contact Information
John Higuchi, CEO of Aciont Inc.
Main phone line: (801) 359-3461; e-mail:  admin@aciont.com